Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SFDA To Strengthen Electronic Monitoring Of Drugs

This article was originally published in PharmAsia News

Executive Summary

By building a national surveillance network on the special drug monitoring platform launched last October, China State FDA will further strengthen electronic drug monitoring by gradually phasing in an electronic identification system. Anesthetics and category 1 psychotropic drugs are already under surveillance, while key pharmaceutical production and circulation companies will be mandated to electronically tag category 2 psychotropic drugs, plasma products, vaccines and TCM injections by Oct. 31. SFDA will draw up a catalog that includes all approved registered drugs to be entered in the surveillance network; firms involved must stick standard electronic codes on their smallest product packs before marketing. Once the electronic network is established, consumers may check on drugs by calling or go online via mobile phones. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068190

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel